Propylallyltryptamine (PALT), also known as N-propyl-N-allyltryptamine or by its developmental code name ASR-3004, is a serotonin receptor modulator of the tryptamine family. It is an asymmetrical analogue of dipropyltryptamine (DPT) and diallyltryptamine (DALT). The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT<sub>1B</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>6</sub> receptors, but not of the serotonin 5-HT<sub>1A</sub> receptor. It is also a serotoninâÂÂnorepinephrineâÂÂdopamine reuptake inhibitor (SNDRI). The chemical synthesis of PALT has been described. A notable analogue of PALT is iPALT (ASR-3003). PALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.